article thumbnail

Top Life Science News and Trends in 2023 at Xtalks

XTalks

In 2023, there were significant advancements and notable trends in the life sciences. Xtalks compiled a list of its top life science news and trends of 2023, which provided readers with the latest developments, information and expert insights across life science industries, including pharma, biotech and medical device.

article thumbnail

Top 15 Diabetes Drugs in 2023 by 2022 Sales Statistics

XTalks

Diabetes remains a critical global challenge, affecting millions of lives and commanding significant attention from the medical, life sciences and pharmaceutical sectors. Read on to learn more about the top 15 diabetes drugs in 2023, based on 2022 sales statistics. mL subcutaneous solution (2 mg/1.5 billion in Q4 2022.

Sales 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Eli Lilly Reaches Settlement with Totality MediSpa Over Sale of Compounded Mounjaro and Zepbound

XTalks

Lilly said it discovered some products claiming to be compounded tirzepatide medicines that contained bacteria, high impurity levels, different chemical structures and different colors than Mounjaro or Zepbound. “In In at least one instance, the product was nothing more than sugar alcohol,” said Lilly.

Sales 52
article thumbnail

Tiziana Life Sciences plc (“Tiziana” or the “Company”) – Tiziana Files Registration Statement on Form F-3 with U.S. Securities and Exchange Commission

The Pharma Data

27, 2021 (GLOBE NEWSWIRE) — Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today announces that it has filed a “universal” shelf registration statement on Form F-3 (File No. About Tiziana Life Sciences.

article thumbnail

GSK to move HQ to central London, as Canary Wharf plans filed

pharmaphorum

This week saw two major life sciences investments in London, as GSK unveiled plans to move its headquarters to a central location in the city, while an ambitious plan to develop a new biosciences hub in Canary Wharf moved to the next stage. Earnshaw building. The building will be a “vertical campus” with 823,000 sq.

article thumbnail

Why Mask-Associated Dry Eye Won’t Necessarily Boost Restasis Sales

XTalks

Anti-inflammatory drugs like Restasis and Xiidra are popular treatment options for the condition, but will the emergence of mask-associated dry eye bolster their sales? But if you thought the growing number of patients presenting with mask-associated dry eye would mean higher sales for Restasis, think again.

Sales 119
article thumbnail

Changes to UK Statutory Scheme go ahead despite pharma criticism

Drug Discovery World

This means that companies will pay a rebate on the sales of branded medicines to the NHS of 21.9% Exemptions from payment will be implemented for medicines containing a new active substance, exceptional central procurements and centrally procured vaccines. in 2024, 24% in 2025 and 26.8% in Spain and 8.25% in Ireland.